Condition: Triple Negative Locally Advanced Non-resectable Breast Cancer · HR+, HER2-, Advanced Breast Cancer · Sponsor: Marengo Therapeutics, Inc.
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This description comes directly from the study's public registry record.
Kevin Chin, MD, MS · 617-276-5734 · kchin@marengotx.com
Always discuss trial participation with your own doctor first.
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UCLA Health | Los Angeles, California, United States | Recruiting |
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| UT Health San Antonio MD Anderson Cancer Center | San Antonio, Texas, United States | Recruiting |
| BC Cancer | Vancouver, British Columbia, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06827613